Home LiteratureArticle Details
PMID: 31672769 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Comment

A Solution to the Dilution: The Role for Biomarkers in Advanced Ovarian Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research ·Vol. 26 ·No. 1 ·2020-00-01 ·Pages 9-10

Handley KF, Sood AK

Abstract

Reliable approaches to predict residual disease prior to primary debulking surgery have been sought to further personalize surgical approaches. Reliance on molecular biomarkers alone in a complex clinical environment is challenging and algorithms that incorporate both molecular and clinical features may need to be considered.See related article by Heitz et al., p. 213.

MeSH Terms
Biomarkers Carcinoma, Ovarian Epithelial Cytoreduction Surgical Procedures Female Humans Neoplasm, Residual Ovarian Neoplasms
Chemicals
Biomarkers
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Handley Katelyn F
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sood Anil K
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. asood@mdanderson.org.
References (7)
7 references, click to expand
  1. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
    N Engl J Med. 2010 Sep 2;363(10):943-53 PMID: 20818904
  2. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer.
    Clin Cancer Res. 2014 Jun 15;20(12):3280-8 PMID: 24756370
  3. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples.
    J Natl Cancer Inst. 2014 Apr 03;106(5):null PMID: 24700803
  4. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.
    Lancet. 2015 Jul 18;386(9990):249-57 PMID: 26002111
  5. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.
    Obstet Gynecol. 2018 Sep;132(3):545-554 PMID: 30095787
  6. Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer.
    Clin Cancer Res. 2020 Jan 1;26(1):213-219 PMID: 31527166
  7. Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation.
    Gynecol Oncol. 2015 Dec;139(3):394-400 PMID: 26348314
Article Info
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Abbr.
Clin Cancer Res
ISSN
1557-3265
DOI
10.1158/1078-0432.CCR-19-3072
Email
asood@mdanderson.org
Published
2020-00-01
Epub
2019-00-31
Pages
9-10
Language
English
Region
United States
NLM ID
9502500
PMCID
PMC6942626
Subset
IM
Grants
NCI NIH HHS · P50 CA217685 · United States
NCI NIH HHS · R01 CA227622 · United States
Corrections
CommentIn
PMID: 31527166
CommentOn
PMID: 31527166
External Links
PubMed source DOI: 10.1158/1078-0432.CCR-19-3072 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2